Hims & Hers review
The fastest, lowest-friction way to start brand GLP-1 month-to-month, cash-pay.
Our 31-point methodology score. We take no money from Hims & Hers, or any provider we review. A score is never for sale.
The bottom line
Hims & Hers (5.9/10) is the easy on-ramp: a $39 intro month and quick onboarding for brand Wegovy and Ozempic. It scores lowest in our recommended set on cost transparency and consumer sentiment: the drug is billed on top (realistic all-in ~$298/mo, cash-pay), and owners report friction when cancelling, so read the subscription terms before you start.
How we scored Hims & Hers
Five weighted dimensions, the same for every provider, judged on the evidence alone. The weights are fixed. See the full methodology.
Strengths & watch-outs
What stands out
- Clinical evidence 8.5/10: prescribes FDA-approved, trial-backed medications.
What to watch
- Consumer sentiment 4.0/10: mixed patient reviews and a notable complaint history.
- True cost & transparency 4.0/10: the advertised price is membership-only; the real cost is higher.
- The membership is billed separately from the medication, so the real cost is higher than the sticker.
- The advertised $39 is an intro that steps up to $149/mo.
- Cash-pay only: insurance can’t be applied to the medication.
Every point above traces to the locked scores and the verified pricing, not to anything we earn.
What you’ll pay
The $39 first month (then $149/mo) is the membership only. Brand Wegovy/Ozempic is billed separately, so realistic cash runs about $298/mo.
Price tracking
We baselined Hims & Hers’s advertised price in Jun 2026 and re-check it on a schedule, with no change logged yet. See the full GLP-1 price index.
How this review stays independent
Hims & Hers’s score comes from our 31-point methodology, and we take no money from Hims & Hers or any provider we review: no ads, no affiliate links, no paid placement. See what our independence costs us. Every clinical figure traces to a primary source in our bibliography, and we log every fix in our corrections record. This is evidence reporting, not medical advice. Consult a licensed clinician about eligibility, risks, and benefits.
Compare with other programs we recommend
Or see them all side by side on the comparison page, with a real-cost sort and CSV/JSON export.
Get the monthly research digest
One plain-English email a month: new study findings, price changes, and safety updates. No spam, ever.